ChinaBio Today -- In the last two months, three China life science companies have made their debuts on US exchanges. The most important insight from these IPOs is that they actually took place. In the previous 12 months, the worldwide economic crisis prevented almost all IPO activity, so a completed IPO became reason enough to celebrate. With that being said, the three companies – China Nuokang Bio-Pharma, Concord Medical and China Cord Blood – did not fare particularly well in their debuts. More details...
